DEFA14A: ESSA Pharma Confirms Key Merger Dates with XenoTherapeutics

ESSA Pharma Inc. announced an amended Interim Order from the Supreme Court of British Columbia, confirming key dates for its Special Meeting and court hearing related to the business combination with XenoTherapeutics Inc.

Summary

• ESSA Pharma Inc. received an amended Interim Order from the Supreme Court of British Columbia on September 25, 2025.
• The order pertains to the previously announced Business Combination Agreement with XenoTherapeutics Inc., a non-profit biotechnology company, under which Xeno will acquire all outstanding common shares of ESSA.
• The amended Interim Order approves the Special Meeting date of October 3, 2025, for common shareholders, optionholders, and warrantholders.
• The deadline to deliver notices of dissent is October 1, 2025.
• The Court hearing date for approval of the Arrangement is October 7, 2025.
• The deadline for responses for persons intending to attend the October 7th hearing is October 3, 2025.
• The Special Meeting will reconvene online at 2:00 p.m. (Pacific Time) on October 3, 2025.
• Supplemental proxy materials reflecting previously announced revised transaction terms were filed on September 24, 2025.

Sentiment

Score: 7

Explanation: The filing provides a positive update by confirming the procedural steps and dates for the previously announced business combination, indicating progress towards completion. While it doesn't present new financial gains, it reduces uncertainty regarding the transaction timeline.

Positives

• An amended Interim Order was received, confirming key dates for the business combination, indicating progress towards transaction completion.
• The Special Meeting date of October 3, 2025, and the Court hearing date of October 7, 2025, are approved, reducing uncertainty regarding the transaction timeline.

Negatives

• No explicit negative financial or operational outcomes are detailed in this procedural update.

Risks

• Completion of the Transaction on anticipated terms and timing, including obtaining required securityholder, regulatory, and court approvals, and the satisfaction of other conditions.
• Potential for the date of the Special Meeting to change.
• Potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty, or their respective directors or officers.
• Potential exposure or liability relating to the due bill communication matter that occurred on August 25, 2025.
• Risk that disruptions from the Transaction will harm ESSA's business, including current plans and operations.
• Ability of ESSA to retain and hire key personnel.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.
• Continued availability of capital and financing and rating agency actions.
• Legislative, regulatory, and economic developments affecting ESSA's business.
• Accuracy of ESSA's financial projections.
• General business, market, and economic conditions.
• Certain restrictions during the pendency of the Transaction that may impact ESSA's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, outbreaks of war or hostilities.
• Significant transaction costs associated with the Transaction.
• Possibility that the Transaction may be more expensive to complete than anticipated.
• Competitive responses to the Transaction.
• General business risks detailed in ESSA's Annual Report on Form 10-K dated December 17, 2024, and the definitive proxy statement filed August 11, 2025.

Future Outlook

The filing confirms the procedural steps and dates for the completion of the business combination with XenoTherapeutics Inc. The transaction is expected to proceed towards a court hearing for approval on October 7, 2025, following the Special Meeting on October 3, 2025.

Industry Context

This transaction represents a strategic shift for ESSA Pharma, a pharmaceutical company previously focused on prostate cancer therapies, as it is being acquired by XenoTherapeutics, a non-profit biotechnology company focused on xenotransplantation. XOMA Royalty is involved as a biotechnology royalty aggregator. This could indicate a pivot or exit strategy for ESSA's previous therapeutic focus.

Legal Proceedings

• Potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty, or their respective directors or officers is listed as a risk factor.

Stakeholder Impact

• Shareholders, Optionholders, and Warrantholders: Will vote on the transaction at the Special Meeting on October 3, 2025, and have a dissent right deadline of October 1, 2025. Their shares will be acquired by Xeno.
• Employees: Risk of disruptions from the transaction harming the business, including current plans and operations, and the ability to retain and hire key personnel.
• Customers/Suppliers: Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.

Next Steps

• Special Meeting of securityholders on October 3, 2025, at 2:00 p.m. (Pacific Time).
• Deadline to deliver notices of dissent by October 1, 2025.
• Deadline for responses for persons intending to attend the Court hearing by October 3, 2025.
• Court hearing for approval of the Arrangement on October 7, 2025.
• Completion of the Transaction, subject to obtaining all required approvals and satisfying all conditions.

Key Dates

Recommendation

This filing is a procedural update confirming the timeline for the previously announced business combination. It does not contain new financial performance data or material changes to the transaction terms that would alter an existing investment thesis. Investors would likely maintain their current position ("hold") as the transaction progresses towards its final approvals, awaiting the outcome of the Special Meeting and the Court hearing.

Keywords

ESSA Pharma, XenoTherapeutics, XOMA Royalty, Business Combination, Merger, Acquisition, Biotechnology, Pharmaceutical, SEC Filing, Proxy Statement, Court Order, Special Meeting, Arrangement